A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs OTL 102 (Primary)
- Indications Chronic granulomatous disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 30 Oct 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 30 Oct 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2021.
- 30 Oct 2019 Status changed from recruiting to active, no longer recruiting.